Edward Conner
Fortune : 2 M $ au 30/06/2026
Fortune : 2 M $ au 30/06/2026
Dr. Edward R.
Conner, MD, is a Chief Medical Officer at Jade Biosciences, Inc. Dr. Conner was previously employed as a Chief Medical Officer by Ardelyx, Inc., a Chief Medical Officer by Third Harmonic Bio, Inc., a Chief Medical Officer by Locanabio, Inc., an Independent Director by Imara, Inc., a Division Head-Gene Therapy Medical & Development by Astellas Gene Therapies, Inc., a Chief Medical Officer & Senior Vice President by Sangamo Therapeutics, Inc., a Vice President-Clinical Development by Ultragenyx Pharmaceutical, Inc., a Senior Medical Director by BioMarin Pharmaceutical, Inc., and a Medical Director by Genentech, Inc. He received his undergraduate degree from Duke University and a doctorate degree from The University of California, San Francisco.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARDELYX, INC. 0,12 % | 01/08/2025 | 302 260 ( 0,12 % ) | 2 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| JADE BIOSCIENCES, INC. | Directeur Technique/Scientifique/R&D | 22/04/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
| ARDELYX, INC. | Directeur Technique/Scientifique/R&D | 31/12/2025 |
| THIRD HARMONIC BIO, INC. | Directeur Technique/Scientifique/R&D | 31/07/2025 |
| IMARA | Directeur/Membre du Conseil | 24/02/2023 |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Develops and operates software platform for addressing a wide spectrum of human genetic diseases | Directeur Technique/Scientifique/R&D | 01/06/2022 |
| AUDENTES THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 12 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Ultragenyx Pharmaceutical, Inc.
Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of California, San Francisco
The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ardelyx, Inc.
Ardelyx, Inc. Pharmaceuticals: MajorHealth Technology Discovers and Develops therapeutic therapeutic drugs that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases | Health Technology |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Develops and commercializes gene therapy products for patients with serious rare diseases | Health Technology |
Imara, Inc.
Imara, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes novel therapeutics for patients with sickle cell disease | Health Technology |
Locanabio, Inc.
Locanabio, Inc. Packaged SoftwareTechnology Services Develops and operates software platform for addressing a wide spectrum of human genetic diseases | Technology Services |
Aerovate Therapeutics, Inc.
Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of allergic and immune diseases and disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national